Home Featured Page 47

Featured

Latest

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Regenerative Business in Psychedelics: A Sustainable Path Forward

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated...

Difficult Conversations, the Need for Culturally Competent Care, and Why Representation...

Archetypes, Individuation, and the Shadow: Carl Jung’s Enduring Psychedelic Influence

Vital 4: Informational Session and Q+A, with David

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Kyle

Vital 4: Informational Session and Q+A, with David

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Regenerative Business in Psychedelics: A Sustainable Path Forward

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated...

Difficult Conversations, the Need for Culturally Competent Care, and Why Representation...

Archetypes, Individuation, and the Shadow: Carl Jung’s Enduring Psychedelic Influence

Vital 4: Informational Session and Q+A, with David

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Kyle

Vital 4: Informational Session and Q+A, with David

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY